Any feedback?
Information on EC 1.1.1.141 - 15-hydroxyprostaglandin dehydrogenase (NAD+)
for references in articles please use BRENDA:EC1.1.1.141Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
1.1.1.141 15-hydroxyprostaglandin dehydrogenase (NAD+)IUBMB Comments
Acts on prostaglandin E2, F2alpha and B1, but not on prostaglandin D2. cf. EC 1.1.1.196 15-hydroxyprostaglandin-D dehydrogenase (NADP+) and EC 1.1.1.197 15-hydroxyprostaglandin dehydrogenase (NADP+).
Specify your search results
Word Map
- 1.1.1.141
- cox-2
- cyclooxygenase-2
- fetal
-
arachidonic
- pregnancy
- chorion
- labor
-
pgf2alpha
- indomethacin
-
parturition
-
nsaid
- trophoblast
-
preterm
- myometrium
-
chemoprevention
-
15-keto
-
eicosanoids
-
thromboxane
-
prostanoids
- decidua
- synthase-1
-
nadp-linked
-
15-keto-pge2
-
clubbing
-
cesarean
- osteoarthropathy
- prostacyclin
- amnion
-
beta-hydroxysteroid
-
lipoxins
- calcitriol
-
9-ketoreductase
- medicine
-
slco2a1
-
6-keto-pgf1
- drug development
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
Reaction Schemes
Synonyms
15-pgdh, 15-hydroxyprostaglandin dehydrogenase, prostaglandin dehydrogenase, 15-prostaglandin dehydrogenase, 15-hydroxy prostaglandin dehydrogenase, nad+-dependent 15-hydroxyprostaglandin dehydrogenase, 15-oh-pgdh, nad-dependent 15-hydroxyprostaglandin dehydrogenase, 15-hydroxyprostaglandin-dehydrogenase, 15-hydroxy-prostaglandin-dehydrogenase, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
11alpha,15-dihydroxy-9-oxoprost-13-enoate:NAD+ 15-oxidoreductase
-
-
-
-
15-hydroxyprostaglandin dehydrogenase
15-hydroxyprostanoic dehydrogenase
-
-
-
-
15-OH-PGDH
15-PGDH
dehydrogenase, 15-hydroxyprostaglandin
-
-
-
-
HPGD
NAD+ dependent 15-hydroxyprostaglandin dehydrogenase
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (type I)
-
-
-
-
NAD+-linked 15-hydroxyprostaglandin dehydrogenase
NAD-specific 15-hydroxyprostaglandin dehydrogenase
-
-
-
-
nicotinamide adenine dinucleotide-dependent 15-hydroxyprostaglandin dehydrogenase
-
PGDH
prostaglandin dehydrogenase
15-hydroxyprostaglandin dehydrogenase
-
-
15-OH-PGDH
-
-
-
-
15-PGDH
-
-
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase
-
-
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase
-
NAD+-linked 15-hydroxyprostaglandin dehydrogenase
-
-
PGDH
-
-
-
-
prostaglandin dehydrogenase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ = (5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ = (5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
NAD+ is added first, followed by prostaglandin E2, 15-ketoprostaglandin is released followed by NADH
-
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ = (5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
single displacement mechanism
-
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ = (5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
ordered bi-bi-mechanism
-
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ = (5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
ordered bi-bi-mechanism
-
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ = (5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
displacement reaction mechanism, at pH 7.0 a kinetically significant ternary complex is formed, while at pH 9.0 the ternary complex is not kinetically significant, Theorell-Chance mechanism
-
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ = (5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
residues and domains involved in catalysis and substrate binding, overview
-
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ = (5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
substrate binidng and catalytic mechanism of the enzyme, homology modeling, docking and molecular dynamics simulation, residues Gln148, Ser138, Tyr151, and Lys155 are important, overview
-
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ = (5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
BRENDA
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate:NAD+ 15-oxidoreductase
Acts on prostaglandin E2, F2alpha and B1, but not on prostaglandin D2. cf. EC 1.1.1.196 15-hydroxyprostaglandin-D dehydrogenase (NADP+) and EC 1.1.1.197 15-hydroxyprostaglandin dehydrogenase (NADP+).
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9030-87-9
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
-
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
r
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid + NAD+
(5Z,8E,10E)-12-oxo-5,8,10-heptadecatrienoic acid + NADH
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
15(S)-hydroperoxy-5,8,11,13-(Z,Z,Z,E)-eicosatetraenoic acid + NAD+
15-oxo-5,8,11,13-(Z,Z,Z,E)-eicosatetraenoic acid + NADH
-
-
-
-
?
15-hydroxyeicosatetraenoic acid + NAD+
15-ketoeicosatetraenoic acid + NADH
-
-
-
?
19-hydroxyprostaglandin E1 + NAD+
19-hydroxy-15-oxoprostaglandin E1 + NADH
-
-
-
?
20-hydroxyprostaglandin E1 + NAD+
20-hydroxy-15-ketoprostaglandin E1 + NADH
-
-
-
?
5,6-chrysenequinone + NADH
? + H2O2
-
formation of potentially hazardous semiquinones, reaction mechanism, overview
-
-
?
6-ketoprostaglandin E1 + NAD+
6,15-diketoprostaglandin E1
-
-
-
?
9,10-phenanthrenequinone + NADH
? + H2O2
-
formation of potentially hazardous semiquinones, reaction mechanism, overview
-
-
?
prostaglandin D1 + NAD+
15-ketoprostaglandin D1 + NADH + H+
-
very low activity
-
?
prostaglandin E1 + NAD+
15-ketoprostaglandin E1 + NADH + H+
-
-
-
-
?
prostaglandin E3 + NAD+
15-keto-prostaglandin E3 + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-oxoprostaglandin F2alpha + NADH + H+
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
r
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. prostaglandin E1
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. prostaglandin E1
i.e. 15-ketoprostaglandin E1
r
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
catabolism of (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglnadin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
key step in prostaglandin catabolism, enzyme activation leads to reduced cell proliferation, the enzyme is an antagonist of ibuprofen
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
key step in prostaglandin inactivation
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
PGE2 degradation
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
prostaglandin E2, PGE2, a proinflammatory bioactive lipid, promotes cancer progression by modulating proliferation, apoptosis, and angiogenesis, PGE2 is a downstream product cyclooxygenase and is biochemically inactivated by the enzyme
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells, overview
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
the enzyme is a putative cyclooxygenase-2 antagonist and and tumor suppressor
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
transcriptional regulation and biological functions, the enzyme cooperates with cyclooxygenase-2 to control cellular prostaglandin levels, reciprocal regulation of the two enzymes, overview
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2, inactivation
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2, substrate binding structure analysis, determination of interactions
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
PGE2 degradation
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2, best substrate
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
first step in prostaglandin catabolism
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
the enzyme catalyzes the oxidation of the 15(S)-hydroxyl group of prostaglandin E2 (PGE2), converting the proinflammatory PGE2 to the anti-inflammatory 15-keto-PGE2 (an endogenous ligand for peroxisome proliferator-activated receptor-gamma [PPAR-gamma])
-
-
?
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
-
?
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid + NAD+
(5Z,8E,10E)-12-oxo-5,8,10-heptadecatrienoic acid + NADH
-
-
-
?
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid + NAD+
(5Z,8E,10E)-12-oxo-5,8,10-heptadecatrienoic acid + NADH
-
-
-
?
(5Z,8E,10E,12S)-12-hydroxy-5,8,10-heptadecatrienoic acid + NAD+
(5Z,8E,10E)-12-oxo-5,8,10-heptadecatrienoic acid + NADH
-
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
NAD+ is much more effective than NADP+
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
specific for NAD+
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
specific for NAD+
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
specific for NAD+
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
NADP+ is more effective than NAD+
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
11alpha,15(S)-dihydroxy-9-ketoprost-5,13-dienoic acid + NAD(P)+
11alpha-hydroxy-9,15-diketoprost-5,13-dienoic acid + NADH
-
-
-
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
-
-
-
-
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
-
physiological inactivation of prostaglandin by catalyzing the first step in catabolism
-
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
-
physiological inactivation of prostaglandin by catalyzing the first step in catabolism
-
?
15-hydroxyprostaglandin + NAD+
15-oxoprostaglandin + NADH + H+
-
physiological inactivation of prostaglandin by catalyzing the first step in catabolism
-
?
6-ketoprostaglandin F1alpha + NAD+
6,15-diketoprostaglandin F1alpha + NADH + H+
-
-
-
?
6-ketoprostaglandin F1alpha + NAD+
6,15-diketoprostaglandin F1alpha + NADH + H+
-
-
-
?
prostaglandin A1 + NAD+
15-ketoprostaglandin A1 + NADH + H+
-
-
-
?
prostaglandin A1 + NAD+
15-ketoprostaglandin A1 + NADH + H+
-
-
-
?
prostaglandin D2 + NAD+
15-ketoprostaglandin D2 + NADH + H+
-
-
-
?
prostaglandin D2 + NAD+
15-ketoprostaglandin D2 + NADH + H+
-
-
-
?
prostaglandin E2 + NAD+
15-ketoprostaglandin E2 + NADH + H+
-
-
-
-
?
prostaglandin E2 + NAD+
15-ketoprostaglandin E2 + NADH + H+
-
the wild type enzyme is highly active against prostaglandin E2 and NAD+
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
?
prostaglandin E2 + NAD+
15-oxoprostaglandin E2 + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
NAD+ is much more effective than NADP+
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
specific for NAD+
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
specific for NAD+
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
specific for NAD+
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
NADP+ is more effective than NAD+
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
?
prostaglandin F2alpha + NAD+
15-ketoprostaglandin F2alpha + NADH + H+
-
-
-
?
additional information
?
-
-
the enzyme catalyzes specifically the oxidation of the (15S)-hydroxy group of all natural prostaglandins except the B and 19-hydroxylated types
-
-
?
additional information
?
-
-
dexamethasone and phorbol ester play a role in enzyme regulation in erythroleukemia cells
-
-
?
additional information
?
-
-
key enzyme for metabolic inactivation of prostaglandins, enzyme levels are reduced in inflammatory bowel disease involving TNF-alpha
-
-
?
additional information
?
-
-
the enzyme is a tumor suppressor of human breast cancer, expression of the enzyme and the estrogen receptor is correlated, silencing of the enzyme results in enhanced cancer cell proliferation, the enzyme expression is silenced in vivo in cancer cells due to promoter methylation
-
-
?
additional information
?
-
-
the enzyme is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a medullary thyroid carcinoma cell line
-
-
?
additional information
?
-
-
15-hydroxyprostaglandin dehydrogenase may be repressed by an epigenetic mechanism involving histone deacetylation, resulting in increased prostaglandin E2 activity in tumors
-
-
?
additional information
?
-
-
prostaglandins play an essential role in primate parturition acting on uterine contractility and on cervical ripening
-
-
?
additional information
?
-
-
the enzyme is an in vivo suppressor of colon tumorigenesis, mechanism of conferring increased susceptibility to colon neoplasia, overview
-
-
?
additional information
?
-
-
the enzyme is an in vivo suppressor of colon tumorigenesis, mechanism of conferring increased susceptibility to colon neoplasia, overview
-
-
?
additional information
?
-
-
substrate specificity, overview, no activity with prostaglandin B1
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
-
-
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
r
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+